"Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
| Descriptor ID |
D013926
|
| MeSH Number(s) |
D12.644.276.374.410.240.750 D12.776.395.240.750 D12.776.467.374.410.240.750 D23.529.374.410.240.750
|
| Concept/Terms |
Thrombopoietin- Thrombopoietin
- Megakaryocyte Colony Stimulating Factor
- Megakaryocyte Growth and Development Factor
- Thrombocytopoietin
- mpl Ligand
- Ligand, mpl
- Myeloproliferative Leukemia Virus Oncogene Ligand
- Thrombocytopoiesis-Stimulating Factor
- Thrombocytopoiesis Stimulating Factor
- c-mpl Ligand
- Ligand, c-mpl
- MGDF Factor
|
Below are MeSH descriptors whose meaning is more general than "Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Thrombopoietin".
This graph shows the total number of publications written about "Thrombopoietin" by people in this website by year, and whether "Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombopoietin" by people in Profiles.
-
Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):426-433.
-
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913.
-
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 2012 Nov 29; 5:71.
-
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44.
-
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007 Aug 01; 110(3):986-93.
-
Human umbilical cord blood-derived f-macrophages retain pluripotentiality after thrombopoietin expansion. Exp Cell Res. 2005 Nov 01; 310(2):311-8.
-
Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporation. Bone Marrow Transplant. 2001 Jun; 27(11):1201-9.
-
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
-
Relationship between megakaryocyte mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura. Br J Haematol. 1999 May; 105(2):452-8.
-
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35.